Therapeutic area intelligence for Pancreatic Ductal Adenocarcinoma with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

TQB Biopharma →

Assets

gemcitabine →

SBRT →

TQB2868 →

Recent signals(3)

ClinicalJuly 14, 2026

Sitagliptin Combined with Gemcitabine and Paclitaxel in PDAC Patients

A clinical trial is investigating the efficacy of sitagliptin in combination with gemcitabine and albumin-bound paclitaxel for pancreatic ductal adenocarcinoma.

ClinicalJune 22, 2026

SBRT and IL-12 in PDAC: Local Therapy Alters Bone Marrow Hematopoiesis

Localized SBRT and IL-12 treatment in PDAC showed significant effects on bone marrow, including acute lymphopenia and altered hematopoiesis.

ClinicalJune 17, 2026

Phase 3 Trial of TQB2868 and Anlotinib in Metastatic Pancreatic Cancer Initiated

A randomized, open-label trial is underway to evaluate TQB2868 injection and anlotinib hydrochloride in combination with chemotherapy versus placebo.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Pancreatic Ductal Adenocarcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.